Notice of Special Interest (NOSI): Training Program in Application of Artificial Intelligence in Development of Treatment for Substance Use Disorders)
NOT-DA-26-004
First Available Due Date:
June 12, 2025
- April, 26, 2024 Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed). See NOFO PA-24-179
- April, 26, 2024 Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required). See NOFO PA-24-180
- April, 26, 2024 Independent Scientist Award (Parent K02 - Independent Clinical Trial Required). See NOFO PA-24-178
- April, 25, 2024 Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed). See NOFO PA-24-188
- April, 25, 2024 Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required). See NOFO PA-24-187
- April, 25, 2024 Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required). See NOFO PA-24-189
- April, 24, 2024 Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed). See NOFO PA-24-176
- April, 24, 2024 Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required). See NOFO PA-24-175
- April, 24, 2024 Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required). See NOFO PA-24-177
- April, 24, 2024 Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required). See NOFO PA-24-183
- April, 24, 2024 Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed). See NOFO PA-24-182
- April, 24, 2024 Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required). See NOFO PA-24-181
- April, 24, 2024 NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required). See NOFO PA-24-195
- April, 24, 2024 NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required). See NOFO PA-24-193
- April, 24, 2024 NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed). See NOFO PA-24-194
- April, 09, 2024 Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required). See NOFO PA-24-186
- April, 09, 2024 Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed). See NOFO PA-24-185
- April, 09, 2024 Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required). See NOFO PA-24-184
- September, 12, 2023 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity). See NOFO PA-23-271
- September, 07, 2023 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32). See NOFO PA-23-262
- September, 07, 2023 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30). See NOFO PA-23-261
- August, 16, 2023 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30). See NOFO PA-23-260
- August, 16, 2023 Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31). See NOFO PA-23-272
National Institute on Drug Abuse (NIDA)
The proliferation of large-scale databases and biomedical repositories, accelerated by the transition to electronic health records and calls for increased data sharing, marks a significant shift in biomedical research. The new NIH policy on Data Management and Sharing will further amplify this trend, increasing the quality and accessibility of high-value datasets available for reuse and secondary analysis. Concomitantly, advances in artificial intelligence/machine learning (AI/ML) enable integration and analysis of vast, unstructured multimodal datasets. Computational modeling of complex relationships between small molecules, genes, proteins, neural circuits, and behaviors can be used to advance any stage of the medication development pipeline, including identification of medications suitable for repurposing, design and optimization of new chemical identities, design of regiments and prediction of side effects, to name a few. This data-driven technology has become ripe for full adoption in the development of novel treatments for substance use disorders (SUDs). For example, data from a genes-disease database, a genome encyclopedia, and a database of protein - chemical interactions have been integrated by a knowledge-driven AI-based system with more than 90 million electronic health records to identify ketamine, an FDA-approved medication, as a potential treatment for cocaine use disorder.
The purpose of this Notice of Special Interest (NOSI) is to support workforce development and training in AI/ML to grow new generation of data scientists and promote data science literacy among researchers developing treatments for SUDs.
Areas of Interest:
- De novo design of new synthesizable molecules targeting addiction circuitry using generative AI tools, molecular dynamics simulations, and other advanced computational approaches
- Identification of medications that can be repurposed for treatment of SUDs by modeling based on multiple datasets such as chemical, genetic, and disease databases, electronic health records, clinical trials and scientific literature
- Optimization of promising compounds for SUD treatment to enhance their selectivity, affinity, and efficacy at the target using structural evolution or other AI/ML approaches
- AI-enabled virtual screening of medication candidates for those with high bioavailability, optimal pharmacokinetics, efficient blood brain barrier permeability, minimal toxicity, and desired behavioral responses
- Chemical synthesis design for the most effective synthetic route and ease of manufacturing by application of generative AI trained on databases of chemical reactions and structures
Other potential areas of interest:
- Intelligent neuromodulation protocols guided by AI/ML methods to minimize drug craving, improve impulse control, enhance executive function, reduce dysphoria, etc., for long-term recovery
- Combinatorial approaches designed through computational modeling and directed at multiple treatment targets simultaneously, combining different treatment modalities or different medications with synergistic effects on sustained drug abstinence
- Implementation of AI/ML algorithms to augment existing digital and sensor-based technologies monitoring stress, craving, drug relapse, or overdose
- AI/ML-based software as a medical device (SaMD) to support recovery, prevent relapse and improve treatment outcomes
Application and Submission Information
This notice applies to due dates on or after June 12, 2025 and subsequent receipt dates through September 8, 2028.
Submit applications for this initiative using one of the following notice of funding opportunity (NOFO) or any reissues of these announcement through the expiration date of this notice.
- PA-24-177 - Mentored Research Scientist Development Award (Parent K01 Independent Basic Experimental Studies with Humans Required)
- PA-24-176 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)
- PA-24-175 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)
- PA-24-180 - Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)
- PA-24-178 - Independent Scientist Award (Parent K02 - Independent Clinical Trial Required)
- PA-24-179 - Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed)
- PA-24-183 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Basic Experimental Studies with Humans Required) -
- PA-24-182 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)
- PA-24-181 - Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)
- PA-24-186 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)
- PA-24-185 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)
- PA-24-184 - Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)
- PA-24-188 - Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)
- PA-24-187 - Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)
- PA-24-189 - Midcareer Investigator Award in Patient-Oriented Research (Parent K24 - Independent Basic Experimental Studies with Humans Required)
- PA-24-195 - NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)
- PA-24-193 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)
- PA-24-194 - NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
- PA-23-261 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
- PA-23-260 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)
- PA-23-271 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)
- PA-23-272 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)
- PA-23-262 - Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)
All instructions in the How to Apply - Application Guide and the NOFO used for submission must be followed, with the following additions:
- For funding consideration, applicants must include NOT-DA-26-004 (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.
Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed notice of funding opportunity.
Scientific/Research Contact(s)
Jana Drgonov, Ph.D.
NIDA/DTMC
Telephone: 301-827-5933
Email: jana.drgonova@nih.gov